Stocktoria
IGC Pharma, Inc. IGC
NYSE American · XASE · stock
IGC Pharma, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.3M | $911,000 | $397,000 | $898,000 | $4.1M | $5.1M | $2.2M | $580,372 | $6.4M |
| Gross profit | $619,000 | $733,000 | $442,000 | $194,000 | $113,000 | $115,000 | $132,000 | $82,000 | $218,237 | — |
| R&D expense | $3.7M | $3.8M | $3.5M | $2.3M | $929,000 | $1.0M | $1.3M | $137,000 | — | — |
| SG&A expense | $4.4M | $6.8M | $8.6M | $13.3M | $7.9M | $6.0M | $3.5M | $1.7M | $2.3M | $2.7M |
| Operating income | -$7.4M | -$9.8M | -$11.6M | -$15.4M | -$8.7M | -$6.9M | -$4.6M | -$1.8M | -$2.1M | -$2.9M |
| Interest expense | — | — | — | — | — | — | — | $30,742 | $223,464 | $213,928 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $2,000 | $0 | $14,431 | $579 |
| Net income | -$7.1M | -$13.0M | -$11.5M | -$15.0M | -$8.8M | -$7.3M | -$4.1M | -$1.8M | -$1.9M | -$2.8M |
| EPS (diluted) | $-0.09 | $-0.22 | — | — | — | — | — | — | $-0.07 | $-0.17 |
| Operating cash flow | -$4.8M | -$5.2M | -$7.0M | -$7.5M | -$10.8M | -$8.7M | -$3.3M | -$1.9M | -$1.4M | -$157,702 |
| Free cash flow | -$4.9M | -$5.3M | -$7.4M | -$7.7M | -$12.3M | -$13.1M | -$3.3M | -$2.1M | -$1.5M | -$279,887 |
| Cash & equivalents | $405,000 | $1.2M | $3.2M | $10.5M | $14.5M | $7.3M | $25.6M | $1.7M | $538,000 | $1.5M |
| Inventory | $1.4M | $1.5M | $2.7M | $3.5M | $5.5M | $4.2M | $248,000 | $486,000 | $0 | $162,091 |
| Total assets | $8.7M | $9.9M | $17.2M | $26.8M | $35.9M | $29.0M | $34.5M | $10.9M | $11.3M | $18.9M |
| Total liabilities | $2.4M | $2.6M | $2.3M | $2.9M | $3.1M | $2.4M | $893,000 | $2.8M | $3.9M | $4.9M |
| Shareholders' equity | $6.3M | $7.3M | $14.9M | $23.9M | $32.8M | $26.5M | $33.6M | $8.1M | $7.4M | $13.9M |
Growth · year-over-year · Revenue CAGR -16.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -5.5% | +47.6% | +129.5% | -55.8% | -77.9% | -20.4% | +133.3% | +277.9% | -90.9% | -17.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001326205 · US · as of 2025-03-31. facts plus Stocktoria's own computed scores — not investment advice.